LAHORE: Artificial intelligence (AI) is enabling researchers to uncover new cancer applications for widely used medicines by ...

A diet rich in fat, sugar and ultra-processed foods may do far more harm than previously thought, with new research ...

Panelists discuss how pivotal RVO trial data for aflibercept 8 mg show strong durability and visual outcomes while raising ...

Regeneron shares are up 41% in six months as FDA approvals, strong Dupixent profits and oncology gains lift investor confidence.

China NMPA clears Mabwell’s IND for B7-H3 ADC in combination with PD-1/VEGF bispecific antibody for patients with advanced solid tumours: Shanghai Friday, January 2, 2026, 12:00 ...

XNCR pairs a wholly owned antibody pipeline with XmAb platform partnerships. This way, they get milestones, licensing revenue ...

Outlook Therapeutics faces a pivotal FDA decision for Lytenava on December 31st, following two prior rejections. Read why ...

The FDA issued a third complete response letter for ONS-5010/Lytenava, requesting confirmatory efficacy evidence for wet AMD treatment. Lytenava is an ophthalmic bevacizumab formulation, potentially ...

Corcept sought FDA approval despite finding relacorilant was statistically no better than placebo in one of two Phase III ...

Panelists discuss how trial findings for aflibercept 8 mg and faricimab in RVO demonstrate comparable efficacy and durability ...

Outlook Therapeutics said on Wednesday the U.S. health regulator has declined to approve its drug for a type of eye disease, ...

NovaBridge Also Included in the Highly Regarded Nasdaq Biotech Index, Emphasizing its Position as an Industry Leader Opening ...